UNIVERSITY OF LEEDS

This is a repository copy of *Inflammasome inhibition under physiological and pharmacological conditions*.

White Rose Research Online URL for this paper:
<https://eprints.whiterose.ac.uk/163555/>

Version: Accepted Version

Article:

Caseley, EA orcid.org/0000-0001-7591-143X, Poulter, JA orcid.org/0000-0003-2048-5693, Rodrigues, F et al. (1 more author) (2020) Inflammasome inhibition under physiological and pharmacological conditions. *Genes & Immunity*, 21 (4). pp. 211-223. ISSN 1466-4879

<https://doi.org/10.1038/s41435-020-0104-x>

© The Author(s), under exclusive licence to Springer Nature Limited 2020. This is an author produced version of a paper published in *Genes & Immunity*. Uploaded in accordance with the publisher's self-archiving policy.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Title: Inflammasome inhibition under physiological and pharmacological conditions

Running title: Mechanisms of inflammasome inhibition

Emily A. Caseley^{1*} • James A. Poulter^{1*} • François Rodrigues^{1,2*} • Immunome project consortium for Autoinflammatory Disorders (ImmunAID)⁺ • Michael F. McDermott¹

¹ Leeds Institute of Rheumatic and Musculoskeletal Medicine, St James's University Hospital, Leeds, UK

² AP–HP, Hôpital Tenon, Sorbonne Université, Service de Médecine interne, Centre de Référence des Maladies Auto-inflammatoires et des Amyloses d'origine inflammatoire (CEREMAIA), 75020 Paris, France

Corresponding author: Michael F. McDermott, m.mcdermott@leeds.ac.uk

* These authors contributed equally to this work

+ A list of authors and their affiliations appears at the end of the paper

Abstract

Inflammasomes are key regulators of the host response against microbial pathogens, in addition to limiting aberrant responses to sterile insults, as mediated by environmental agents such as toxins or nanoparticles, and also by endogenous danger signals such as monosodium urate, ATP and amyloid- β (1).

To date at least six different inflammasome signalling platforms have been reported (2, 3). This review focuses on the complex molecular machinery involved in

activation and regulation of the best characterised inflammasome, NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3), and the development of molecular agents to modulate NLRP3 inflammasome function. Activation of the NLRP3 inflammasome induces inflammation via secretion of interleukin-1 β (IL-1 β) and interleukin-18 (IL-18) proinflammatory cytokines, with orchestration of pyroptotic cell death, to eliminate invading microbial pathogens. This field has gradually moved from an emphasis on monogenic autoinflammatory conditions, such as cryopyrin-associated periodic syndromes (CAPS), to the broad spectrum of innate immune-mediated disease. NLRP3 inflammasome activation is also linked to a range of common disorders in humans including type 2 diabetes (4), cystic fibrosis (5), myocardial infarction, Parkinson's disease, Alzheimer's disease (6) and cancers such as mesotheliomas and gliomas (7).

We describe how laboratory-based assessment of NLRP3 inflammasome activation is emerging as an integral part of the clinical evaluation and treatment of a range of undifferentiated systemic autoinflammatory disorders (uSAID) (8), where a DNA-based diagnosis has not been possible.

In addition, this review summarises the current literature on physiological inhibitors and features various pharmacological approaches that are currently being developed, with potential for clinical translation in autoinflammatory and immune-mediated conditions. We discuss the possibilities of rational drug design, based on detailed structural analyses, and some of the challenges in transferring exciting preliminary results from trials of small molecule inhibitors of the NLRP3 inflammasome, in animal models of disease, to the clinical situation in human pathology.

47

48 **Introduction**

49 The inflammasomes are large cytosolic multiprotein complexes composed of an
50 initiator protein, such as a pattern recognition receptor, and an adaptor protein called
51 ASC (apoptosis-associated speck-like protein containing a caspase recruitment
52 domain (CARD)), which oligomerize to form an activating platform for an effector
53 protein, pro-caspase-1. In addition to proinflammatory cytokine production and
54 mediation of pyroptosis, inflammasomes also regulate the extracellular release of
55 alarmins, such as high mobility group box 1 (HMGB1) protein, from both infected and
56 activated immune cells, which promote cell proliferation and differentiation, with
57 associated inflammation (9).

58

59 **Inflammasome pathways**

60 Hyperactivation of inflammasomes, either by genetic or environmental insult, may
61 result in a wide range of pathological conditions, characterised by recurrent episodes
62 of systemic and organ-specific inflammation (6). Despite the identification of a
63 growing number of SAID disease genes, 40-60% of those with a typical SAID
64 phenotype remain without a definitive diagnosis and, therefore, may be classified as
65 having an uSAID (4). Inhibition of particular inflammasomes, or of the cytokines they
66 release, have shown significant promise as treatments for both monogenic and
67 uSAIDs, and this approach continues to be developed (10). The complex molecular
68 mechanisms regulating the different inflammasomes means that it is key to identify
69 the factors triggering inflammation in order to prescribe the optimal therapies. These
70 complexities are a major cause of the variability in response currently associated

with therapies of various undifferentiated SAIDs, which may range from little or no effect to the development of severe adverse reactions (11).

In recent years, the discovery and classification of disorders as SAIDs, and an increased understanding of mechanisms of inflammasome activation (6, 12), have accelerated the development of therapeutics which target these mechanisms, such as IL-1 inhibitors, of which there are three currently being used in clinical practice. These are anakinra, a recombinant form of the receptor antagonist, IL-1Ra; rilonacept, a soluble chimeric Fc fusion protein of IL-1R1 and IL-1R3, and canakinumab, a monoclonal antibody that specifically neutralises IL-1 β (13). These have all been shown to be highly effective for the treatment of NLRP3 inflammasome-related disorders, as well as in other conditions caused by activation of the NLRC4-inflammasome (14). Given their effectiveness in NLRP3 inhibition, further small molecule inhibitors of NLRP3 have been sought (15-17). The essential requirement of a structurally wild-type NACHT domain, however, is hindering their potential use in humans. According to the INFEVERS website [accessed 10/05/20] (18), 69/109 (63.3%) of pathogenic, or likely pathogenic, NLRP3 mutations are within this domain, which are predicted to impair inhibition by small molecules targeting the NLRP3 NACHT domain, such as MCC950 (19). Inhibition by these small molecules may still be effective, however, for individuals harbouring mutations elsewhere in the gene, such as the C-terminal region (20). These examples highlight the difficulties facing the clinician in identifying an effective therapeutic, and also underline the need to understand the underlying disease mechanism to choose the most appropriate therapeutic for each individual.

95 **Stratification of SAIDs**

96 Stratification of SAIDs is one method which will contribute to more effective
97 therapeutic choices. Many clinical trials of potential therapies have produced
98 negative results, likely because of differing molecular pathways being involved in
99 individuals with the same clinical diagnosis. In a recent study, de Jesus et al.
100 undertook three independent screening methods in parallel to pinpoint disease
101 pathology in patients with an uSAID (21). The authors managed to classify or
102 diagnose 79% of cases (n=52/66). DNA sequencing was the most effective method,
103 but this can often take time. The IFN-response-gene score, combined with cytokine
104 analysis, may therefore be a more effective short term approach (22). Even with a
105 known molecular pathology, targeting of a pathway may not lead to an effective
106 therapeutic. The identification of caspase 1 as the final step of the inflammasome
107 pathway led to many programs developing caspase 1 inhibitors; however, very few
108 made it to clinic (23).

109 Another method used to diagnose and stratify patients with uSAIDs is the
110 identification of disease-specific biomarkers. In order to be an effective biomarker, a
111 molecule must be secreted into an accessible tissue (e.g. serum or urine), be
112 specific to a disease (or class of diseases), be stable outside of the body and
113 detectable using a suitable diagnostic method. A few obvious biomarkers of
114 inflammation, such as serum IL-1 β levels, are already being used to diagnose
115 inflammatory disorders, as well as to guide therapeutic decision making (24). The
116 development of high-content, high-throughput systems, however, have enabled the
117 screening of larger numbers of biomarkers in large sample cohorts (25, 26). The
118 major limiting factor now facing diagnostic laboratories is the paucity of validated,
119 reliable and detectable biomarkers. This ability to screen patients and identify not only

their disease, but also a therapy targeted to their specific disease, is the ultimate goal for personalised medicine.

Stratification of SAIDs using a genetics approach is becoming more widely used, with recent studies suggesting that a molecular diagnosis can be obtained in up to 60% of cases, allied to potential novel insights into the underlying conditions. Despite this, there are limited options for many rare disorders, either due to a lack of effective therapeutics or knowledge limitations regarding the effects of available therapeutics. Identifying biomarkers that are clinically actionable, such as elevated IL-1 β , may, therefore, be more useful for therapeutic decision making than identifying the underlying pathogenic mutation(s).

Physiological inhibitors of the NLRP3 inflammasome

In addition to known pharmacological inhibitors, a number of physiological inhibitors, or negative regulators, of the NLRP3 inflammasome have been discovered. Further research into these physiological inhibitors is likely to drive future drug development to modulate the various mechanisms leading to inflammasome activation, rather than current pharmacological therapies that target the subsequent downstream effects such as cytokine release. Known physiological NLRP3 inflammasome inhibitors have a range of functions, such as inhibition of NLRP3 translation or suppression of oligomerisation. While a brief overview of these mechanisms is described below, a detailed breakdown can be found in Supplementary Table 1.

A reduction in the level of intracellular NLRP3 is one mechanism whereby the NLRP3 inflammasome can be inhibited. The 3'-UTR of *NLRP3* in particular contains

144 conserved regulatory sequences, that may be targeted by at least four different
145 micro-RNA's (miR's). When over-expressed, these miR's result in reduced NLRP3
146 protein production, inflammasome activation and IL-1 β release. Furthermore,
147 transcriptomic analysis has revealed that miR-223 levels, in particular, are inversely
148 proportional to NLRP3 protein (27). In addition to miRs, the RNA binding protein,
149 tristetraprolin, functions by a similar mechanism to reduce NLRP3 expression.
150 Protein degradation is another mechanism by which intracellular NLRP3 levels can
151 be reduced. E3-ubiquitin ligases that promote ubiquitination of NLRP3, resulting in its
152 degradation by the proteasome or the phagosome, have also been identified as
153 effective negative regulators.

154 In the presence of NLRP3, further inhibition of inflammasome formation can be
155 mediated through suppression of oligomerisation. Several direct interactors of
156 NLRP3, such as HSP70 and Kir6.1, have been identified as key negative regulators,
157 by holding NLRP3 in an inactive state and thus unable to bind ASC (Supplementary
158 Table 1). One exception is Sirtuin-2, an NAD-dependent deacetylase, which doesn't
159 bind NLRP3 directly, but instead uses microtubules to prevent NLRP3 and ASC
160 coming into close proximity (28). In addition to physical separation of NLRP3 and
161 ASC to prevent formation of the inflammasome, Sirtuin-2 can also deacetylate
162 NLRP3 to suppress oligomerisation. Phosphorylation of Ser-295 by protein kinase A
163 (PKA) also impairs inflammasome assembly, by the loss of NLRP3 ATPase activity
164 (29). A family of inflammasome inhibitors, known as PYRIN domain-only proteins
165 (POPs) and CARD-only proteins (COPs) have also shown promise as inhibitors of
166 the inflammasome, by binding to NLRP3, or other regulatory proteins such as NF-
167 κ B, to block its activation (30). While these proteins are endogenously expressed, it

168 remains unclear to what effect they respectively inhibit inflammation in unstimulated,
169 inflammasome stimulated and mutation-containing cells.

170 The NLRP3 inflammasome is highly sensitive to homeostatic changes in the
171 cytosol, with changes in potassium ion concentrations able to trigger inflammation.
172 Loss of proteins involved in the regulation of potassium ion efflux can, such as
173 LPIN2, therefore result in NLRP3 inflammasome activation. This includes proteins
174 that interact and regulate the ATP-induced opening of the P2X7 receptor channel, a
175 key receptor for triggering NLRP3 inflammasome activation (31).

176 Failures in autophagy and mitophagy have both been linked with NLRP3
177 inflammasome activation. NLRP3 has been shown to bind key autophagy-associated
178 proteins, such as unc-51 like autophagy activating kinase 1, which facilitate
179 degradation of proteins, including NLRP3 itself. Mitochondrial defects, resulting in an
180 increase in cytosolic reactive oxygen species (ROS), are also known to cause
181 increased NLRP3 activation, with evidence of this process being reversed by the
182 addition of anti-oxidants (32).

183 A key function of the NLRP3 inflammasome is the activation of pro-caspase-1 into
184 its active form, which in turn cleaves cytokine precursors such as pro-IL-1 β . A failure
185 to recruit and activate pro-caspase-1 is, therefore, a mechanism by which the effects
186 of NLRP3 inflammasome activation can be negated. Loss of the caspase-1 inhibitor
187 Flightless-1, or either of its known adaptor proteins, BCAP and LRRFIP2, have been
188 shown to result in reduced levels of active caspase-1 and IL-1 β , following NLRP3
189 inflammasome activation (33, 34).

190 Although targeting of negative regulators of the NLRP3 inflammasome, or of the
191 cellular mechanisms they regulate, may be effective for disorders driven by

overactive NLRP3 inflammasomes, they may not be effective for all patients harbouring NLRP3 activating mutations. This is due to nature of the mutations altering protein binding sites, particularly around the NACHT domain (Fig. 1). Further research is therefore required to determine the effects of specific pathogenic variants on inflammasome inhibition.

Influence of CAPS mutations on NLRP3 inflammasome regulation

Gain-of-function mutations in *NLRP3* lead to CAPS, which encompass neonatal-onset multisystem inflammatory disease (NOMID), also known as CINCA (chronic infantile neurological cutaneous and articular syndrome), Muckle-Wells syndrome (MWS), and familial cold auto-inflammatory syndrome (FCAS). This group of disorders range in severity, but all are characterised by increased release of proinflammatory cytokines, particularly IL-1 β and IL-18, leading to systemic inflammation (35). Whilst there is an extensive database of documented *NLRP3* sequence variants (18), many of which are confirmed to be related to disease states in humans, the mechanisms by which these mutations lead to pathologies are often largely overlooked.

CAPS mutations are known to disrupt various intrinsic processes that control NLRP3 regulation, for example post translational modifications, such as phosphorylation, ubiquitination and sumoylation, which have been widely reviewed (36-38). Phosphorylation has been established as a vital regulatory post-translational modification by which different signalling pathways can be recruited to both positively and negatively regulate NLRP3 activity (39). Mortimer et al. scrutinised PKA inhibition of NLRP3, which is instigated by the binding of prostaglandin E2 (PGE2) to

the EP4 prostanoid receptor, which in turn induces the cyclic adenylyl monophosphate (cAMP)-mediated stimulation of PKA (Fig. 2). This particular study showed that PKA directly inhibits the human NLRP3 inflammasome through disassembly of ASC oligomers, a process dependent on the PKA-mediated phosphorylation of Ser295 (29). This amino acid is located within the nucleotide-binding domain (NBD), and its modification therefore attenuates NLRP3 ATPase function. Furthermore, of the seven Ser295-adjacent CAPS mutations tested (I290M, M301V, G303S, E306K, Q308K, G309S or F311L) (Fig. 2), all but M301V were unresponsive to rapid cAMP-induced inhibition. Additionally, the inhibition of NLRP3-mediated cleavage of IL-1 β by PGE2 required significantly higher (10- to 100- fold) concentrations of PGE2 in PBMCs from CAPS patients with mutations in the NBD domain compared to their WT equivalents. Notably, PBMCs from patients harbouring the Ser295-proximal MWS-related mutations, D303N and E313K, were less sensitive to inhibition of mature IL-1 β release in response to physiologically relevant PGE2 concentrations (40). Together, these studies suggest a way in which these disease-related mutations may result in poorly regulated inflammasome activation.

In addition to PKA, Ser295 is phosphorylated by protein kinase D (PKD). A study by Zhang et al. showed that NLRP3 inflammasome activators cause mitochondria-associated endoplasmic reticulum membranes to localise to the Golgi, and that NLRP3 is recruited to these membranes. Associated with this is an accumulation of diacylglycerol, which recruits PKD, and its phosphorylation of Ser295 is both necessary and sufficient for NLRP3 inflammasome activation (Fig. 3) (41). This study concluded that PKD inhibition can block NLRP3 activity in PBMCs taken from patients exhibiting uncontrolled inflammasome activation. However, the mutations tested, T436N and R260W, are further away from Ser295 than those previously

examined (Fig. 3) (29), and, as such, testing whether CAPS-related mutations proximal to Ser295 are sensitive to PKD inhibition would be valuable. As previously noted, it is also possible that Ser295 phosphorylation plays multiple roles regarding NLRP3 inflammasome activation, and that a process of sequential phosphorylation and dephosphorylation may exist.

Bruton tyrosine kinase (BTK) has also been proposed to play a role in NLRP3 inflammasome regulation. BTK inhibition reduces NLRP3-mediated IL-1 β release from MWS PBMCs (42), although the precise role of BTK with respect to the NLRP3 inflammasome is still under debate, due to evidence that BTK deficiency leads to exacerbated inflammasome activation (43). BTK-mediated phosphorylation of multiple NLRP3 tyrosines (Y136, Y140, Y143 and Y168) (Fig. 4) has been implicated as a molecular switch of inflammasome activity by weakening phosphatidylinositol 4-phosphate (PtdIns4P) interactions, resulting in shorter retention to the Golgi with enhanced NLRP3 inflammasome oligomerisation and increased IL-1 β secretion (Fig. 4) (44). When mapped onto the NLRP3-NEK7 cryogenic electron microscopy (cryo-EM) structure (45), Y168 is in the vicinity of several likely pathogenic CAPS mutations, as well as a putative ADP molecule, and thus may influence nucleotide binding (Fig. 4) (44). This may provide valuable insights into a further mechanism impacting NLRP3 inflammasome regulation.

In addition to impacting phosphorylation-mediated NLRP3 regulation, CAPS mutations may affect sumoylation. Lys689, specifically, has been identified as a site of both ubiquitination and sumoylation in human NLRP3 (Fig. 5) (46, 47). Sumoylation negatively regulates NLRP3 at multiple sites, and mutation of Lys689 results in hyperactivation of NLRP3, which phenocopies that seen in CAPS patients (47). Although the introduction of single disease-related mutations (R260W, E690K

and E692K) did not reduce the overall level of NLRP3 sumoylation, it was suggested in this study that the similarity in phenotype between the K689R mutant and disease-related E690K and E692K mutants may be due to their location in the predicted SUMO motif surrounding K689, leading to disrupted inflammasome regulation (47).

Besides post-translational modifications, interactions between NLRP3 and other proteins are also influenced. Caspase recruitment domain-containing protein 8 (CARD8), also known as Cardinal, is one such protein. CARD8, a member of the CARD family, consists of an N-terminal function to find (FIIND) domain and a C-terminal CARD domain, and genetic alterations in *CARD8* have been associated with numerous inflammatory diseases (48). CARD8 is a negative regulator of NLRP3, which inhibits IL-1 β release by interacting with the NACHT domain (49, 50). A frameshift variant of CARD8, which results in loss of the FIIND and CARD domains, failed to interact with the NACHT domain of NLRP3, and has been implicated in the pathogenesis of a childhood syndrome called periodic fever with aphthous stomatitis, pharyngitis, and cervical adenitis (51). Similarly, the disease-associated NLRP3 mutants R260W, D303N, N477K and H312P all abolish the interaction between CARD8 and NLRP3, and, as a result, IL-1 β secretion is not reduced following CARD8 overexpression, as seen with the WT form. It has been postulated that changes in local structure caused by these polymorphisms may disrupt certain interactions between NACHT and CARD8 (50). Additionally, loss of CARD8 binding is associated with diminished NLRP3 serine phosphorylation (52), suggesting this as an additional mechanism by which CAPS mutations, in disrupting CARD8-NLRP3 interactions, cause disease states.

NIMA-related kinase 7 (NEK7) is a highly conserved serine/threonine kinase which acts as a regulator of mitotic processes (53) that has been identified as a mediator of

the NLRP3 inflammasome (54-56). This regulation occurs independently of its kinase activity (54, 55), but is dependent on interactions between NEK7 and the central NOD domain and leucine-rich repeats (LRRs) of NLRP3. This was initially determined by using deletion mutants, followed by the cryo-EM structure of NLRP3, which showed the C-terminal lobe of NEK7 nestled against the curved LRR and globular NACHT domains of NLRP3. Although mutations in the LRR domain are less frequently reported, this region is implicated several pathologies; NLRP3 harbouring the NOMID-related missense mutations, G755A and G755R (57, 58), in the LRR domain bind to NEK7 with a higher affinity than the WT protein, whereas the hypomorphic missense NLRP3 mutant, D946G, associates less strongly (Fig. 6) (55). Additionally, oridonin, the bioactive component of *Rabdosia rubescens*, which is often used in traditional Chinese medicine to treat inflammatory disorders, has recently been identified as directly targeting NLRP3 (16). Oridonin binds covalently to Cys279 in the NACHT domain, thereby blocking the NLRP3/NEK7 interaction and preventing formation of the inflammasome complex [29]. Together, this indicates that some CAPS mutations could cause amplified inflammatory responses by stabilising the binding between NLRP3 and NEK7, and that a fine-tuned binding affinity between these proteins is vital for normal NLRP3 inflammasome function.

Most CAPS mutations, as identified in the Infevers database (18), can be found in the NACHT domain, surrounding the ADP binding site (59) (Fig. 1). Within the NACHT domain are found both a Walker A motif, which mediates ATP binding, and a Walker B motif, responsible for ATP hydrolysis (60). These two sites are vital to efficient inflammasome function, since ATP binding is required for both the normal functioning of WT NLRP3, and for the constitutive activity of disease-associated mutants (61). This has been further highlighted by the fact that NLRP3 inhibitors bind

to these motifs; MCC950 directly binds to the Walker B motif (62) and CY-09 to the Walker A motif (17), thereby preventing NLRP3 inflammasome function. Determination of NLRP3 by cryo-EM has allowed a series of validated CAPS mutations to be mapped onto the structure and examined in greater detail. Residues D303 and E304, both associated with NOMID/MWS in humans (63, 64), are located on the Walker B motif of the ATPase, and, as such, may directly influence 'sensing' of the nucleotide-binding state. It seems likely that these mutations affect nucleotide binding and hydrolysis and, consequently, NLRP3 inflammasome activity, although current studies have not investigated the effects of NLRP3 mutations on their affinity for nucleotide binding.

Inflammasomes and structures of their components

To date, several inflammasomes structures and their integral components have been determined. The NLRC4 inflammasome structure has arguably been the most thoroughly explored, with high resolution cryo-EM (65) and crystal (66) structures in their inactive and active states, in addition to a cryo-EM structure of the NLRC4 CARD filament (67). However, recent efforts have also resulted in the publication of a cryo-EM structure of inactive human NLRP3, in complex with NEK7 (45). This represents a potentially huge leap forward in our ability to investigate the most studied of the inflammasomes, both in terms of its intrinsic function and for future inhibitor design.

The greater availability of structural information has aided the understanding of the functional roles of the NLRP3 domains, for example the N-terminal pyrin domain (PYD). This plays a vital role in mediating NLRP3 inflammasome assembly via high-

affinity PYD/PYD interactions between NLRP3 and ASC (68), the latter also forming a CARD/CARD interaction with caspase-1 (69). A crystal structure of the NLRP3 PYD revealed a canonical 6-helical bundle structural fold, similar to other PYDs, and the charged peripheral surface, which largely facilitates the NLRP3-ASC interaction by charge complementarity (70). One notable aspect of the structure was a highly conserved disulfide bond present between the PYD and the nucleotide-binding site domain (70). This bond has been suggested to be involved in NLRP3 inflammasome sensitivity to altered redox states, mediated by ROS (71), highlighting a potential regulatory mechanism.

The central NACHT domain possesses ATPase activity, and comprises an NBD, helical domain 1 (HD1), winged helix domain (WHD) and helical domain 2 (HD2). The recently determined NLRP3 cryo-EM structure featured the globular NACHT domain with ADP bound to the NBD (45). This structure gave some valuable insights, including into the CAPS mutations primarily localised to the NACHT domain as described above (18). Mapping of the validated pathogenic NLRP3 mutations showed that the majority surround the ADP-binding site (Fig. 1), potentially affecting the inactive conformation of NLRP3 and thereby enhancing inflammasome activation (45). In addition, when modelled onto the previously determined NLRC4 oligomer structure (66), a 90° rotation of the NBD and HD1 regions relative to the WHD, HD2 and LRR, likely necessary for oligomerisation and activation, was observed (45).

The LRR domain has previously been implicated in the recognition of stimuli, mediation of protein-protein interactions and maintaining the inflammasome in an inactive state (72, 73). The deubiquitinase, BRCC3, has been shown to mediate a regulatory mechanism by which ubiquitinated NLRP3 remains inactive until priming signals initiate BRCC3-mediated deubiquitination of the LRR domain, allowing

365 NLRP3 to oligomerise (74). However, more recent structural and functional studies
366 have raised questions concerning the role played by the LRR domain in the NLRP3
367 inflammasome.

368 LRR domains vary between inflammasomes; in NLRP3 this domain consists of 12
369 repeats encircling NEK7. The main protein-protein interactions exist between NEK7
370 and the LRR and NACHT domains of NLRP3, and mutagenesis identified the
371 interactions between the LRR and NACHT HD2 domains in NLRP3, and the first half
372 of the C-lobe of NEK7 to be the most essential (45). Indeed, NEK7 with the second
373 half of the C-lobe removed, which interacts with the NACHT domain, still binds to
374 NLRP3 (54), highlighting the importance of the LRR domain in this interaction.
375 Additionally, of the two major NLRP3 isoforms identified in humans, the variant
376 lacking exon 5 resulting in a truncated LRR domain, exhibits a loss of activity due to
377 a lack of NLRP3-NEK7 interaction (75).

378 At first glance, there is clear evidence for the LRR domain playing an important role
379 in NLRP3-NEK7 interactions, which are known to be important due to the essential
380 role NEK7 plays in inflammasome function (54, 55). However, other studies have
381 shown that this domain is not required for NLRP3 activation. NLRP3 mutants lacking
382 LRRs are constitutively active when expressed in THP-1 (76) or HEK293T (77) cells.
383 Furthermore, of the more than 20 NLRP3 variants produced by Hafner-Bratković et
384 al., macrophages expressing NLRP3 lacking all LRRs responded to canonical stimuli
385 to a comparable degree to that seen in the WT protein (78). Together, these studies
386 indicate that further investigation is required to delineate the role of the LRR domain
387 in NLRP3 regulation, and that a structure of NLRP3 in the active state would be
388 invaluable.

389

390 **NLRP3 inflammasome inhibitors – design and target identification**

391 Current small molecule inhibitors of the NLRP3 inflammasome were largely
392 discovered prior to publication of the NLRP3/NEK7 cryo-EM structure (45), limiting
393 the opportunities for rational drug design. Some inhibitors have been discovered by
394 elucidating the mechanisms by which existing medicines work, for example oridonin,
395 the major active constituent of many traditional Chinese medicines, directly targets
396 the NLRP3 inflammasome (16). Similarly, tranilast was originally recognised as an
397 anti-allergic agent (79) but was later found to bind the NACHT domain directly (80).
398 Screening of compound libraries has also proven effective when discovering novel
399 inhibitors. For example, 3,4-methylenedioxy- β -nitrostyrene (MNS) was found through
400 the screening of a library of 160 kinase inhibitors (81), and CY-09 resulted from
401 optimisation of the structure of C172, an inhibitor identified through screening of an
402 in-house bioactive compound library (17). Both Bay 11-7082, along with several
403 structurally related vinyl sulfone compounds, and BOT-4-one, were discovered via
404 screening NF- κ B inhibitors (82, 83), and MCC950 (initially named CP412,245, then
405 CRID3), arguably the best characterised NLRP3 inhibitor, was found in a rational
406 screen for inhibitors of IL-1 β production consisting of pharmacological agents known
407 to affect ion transport activity. This study identified a series of diarylsulfonylurea-
408 containing compounds structurally related to glyburide, including MCC950, which
409 was later found to inhibit NLRP3 specifically (84).

410 Whilst these methods have delivered a wide range of antagonists, the NLRP3
411 structure, with advancement in our understanding of inflammasome structure that
412 this represents, has opened up avenues for the rational design of NLRP3

modulators. Existing inhibitor binding sites have also become clearer; for example, the NACHT domain is the site of action for many well-known inhibitors including MCC950, which was shown in a pair of associated studies to interact with the NACHT domain Walker B motif (19, 85). Therefore, this information could signify an important advancement in rational drug design, which is becoming more common with the increasing availability of protein structures (86). As the NLRP3 structure was recently determined at the time of publication (45), it is too early to say whether this approach will be adopted for the development of NLRP3 inflammasome inhibitors. Few published studies have explored the structure of NLRP3, or related proteins, as a basis for virtual screening. Abdullaha et al. have produced a homology model of NLRP3, based on the crystal structure of the NLRC4 inflammasome (66), and used this to dock and develop compounds based around a 2-aryl quinazolin-4(3H)-one scaffold (87). In contrast, Pal et al. used the structures of the human NLRP3 PYD (70) and the human ASC pyrin domain filament (88) to design α -helical stapled peptides capable of targeting the ASC PYD and disrupting ASC filament formation (89). Whilst this represents the beginning of a potentially burgeoning field of structure-based NLRP3 inflammasome inhibitor design, whether this approach will be widely adopted is yet to be seen.

NLRP3 inhibitors in clinical trials

As the NLRP3 inflammasome is directly involved in the pathogenesis of many different diseases, inhibitors of NLRP3 activation are being rapidly developed for a wide range of human disorders, including autoinflammatory, metabolic,

cardiovascular and neurodegenerative conditions. NLRP3 inhibitors currently undergoing clinical trials are described below and summarised in Table 1.

Diacerein is an anthraquinone, an aromatic organic compound approved in Europe and in the USA for treatment of osteoarthritis (90). In a model of gout, it was shown to suppress protein expression and activity of caspase-1, as well as formation of NLRP3 inflammasome complexes, as visualised by confocal microscopy (90). Its ointment formulation, AC-203, has also received FDA approval for the treatment of generalised severe epidermolysis bullosa simplex (91). This genetic condition is a blistering skin disease with neutrophilic inflammation, associated with mutations in the *KRT5* or *KRT14* genes, encoding keratin 5 and keratin 14 proteins respectively. Diacerein is currently being tested in phase II clinical trials for epidermolysis bullosa simplex and ocular surface disease (clinicaltrials.gov identifiers NCT03389308 and NCT04351100, respectively).

Dapansutril (OLT1177) is a β -sulfonyl nitrite compound that inhibits NLRP3 ATPase activity and NLRP3-dependent ASC specks aggregation (92). Dapansutril has been shown to reduce acute gout pain and inflammatory biomarkers in a phase IIA trial (93). It is currently being developed in phases I/II for systolic heart failure and Schnitzler's syndrome (clinicaltrials.gov identifiers NCT03534297 and NCT03595371, respectively).

Inzomelid is an oral, brain-penetrant inhibitor of NLRP3-containing inflammasomes; a phase I trial has been completed and it has alleviated symptoms in one CAPS patient (94). A phase II study for CAPS is being planned (94). The brain-penetrant nature of this inhibitor raises the possibility that this selective, small molecule

459 inhibitor of the NLRP3 inflammasome will soon be tested in neurodegenerative
460 disorders.

461 Tranilast is a tryptophan analog that inhibits NLRP3-induced ASC speck formation,
462 and IgE-induced histamine release from mast cells. It is in clinical use in Japan,
463 China and South Korea, to treat asthma, allergic conjunctivitis and hypertrophic
464 scars (95). Affinity precipitation assays of biotinylated tranilast have showed that this
465 compound directly binds to NLRP3 and thereby impedes its oligomerisation (80). A
466 phase II study of tranilast in CAPS is currently recruiting, and trials are also planned
467 for sarcoidosis, scleredema diabeticorum and mucinosis (clinicaltrials.gov identifiers
468 NCT03923140, NCT03528070, NCT03512873 and NCT03490708, respectively).

469 No human clinical trial is currently registered for MCC950, to the best of our
470 knowledge. Of note, a phase II study has been conducted in rheumatoid arthritis but
471 was interrupted because of liver enzyme elevation in the treatment group (96).

472 Although not directly interacting with NLRP3, the most promising agent that
473 modulates innate immune activation in neurological disorders is masitinib, a tyrosine
474 kinase inhibitor targeting c-KIT (97). C-KIT is a receptor tyrosine kinase constitutively
475 expressed by mast cells and macrophages, and intriguingly, masitinib has also been
476 revealed to act as an NLRP3 activator in BMDMs (98). Masitinib also inhibits other
477 significant kinases, such as Lyn and Fyn, in microglial cells and macrophages (97,
478 99). Masitinib slowed the progression of lateral amyotrophic sclerosis in a
479 randomised placebo-controlled study (99) and has also been reported to delay the
480 evolution of primary progressive and non-active secondary progressive multiple
481 sclerosis (100). A phase III study is currently ongoing in Alzheimer's disease, with an
482 interim analysis showing a positive trend in one of the treatment arms (101). Defining

the cell-specific impact of masitinib on the human NLRP3 inflammasome is likely to increase our understanding of neurodegenerative and neuroinflammatory disorders in the near future.

Future directions

NLRP3 inflammasome activation is linked to a much wider range of human diseases than autoinflammation, namely cardiovascular, neurodegenerative, neuroinflammatory and oncologic conditions. In CAPS, a given NLRP3 inhibitor may only work on a small proportion of patients and treatment will probably be tailored to each mutation. In neurological disorders, NLRP3 inhibitors could be revolutionary, since few treatments are currently effective, although blood-brain barrier penetration and cell-specific targeting of inflammation will be decisive to tailoring therapy and reducing side effects. NLRP3 inhibition in cancer is in its infancy but holds great potential. Indeed, arsenic compounds, already approved in promyelocytic leukemia, are direct inhibitors of NLRP3 (102). Another example is acute lymphoblastic leukemia, where glucocorticoid resistance is caused by NLRP3 overactivation, and is reversed by caspase-1 inhibitors (103). In the field of polygenic inflammatory diseases, NLRP3 inhibitors will compete with disease-modifying anti-rheumatic drugs (DMARDs), many of which, such as methotrexate (104), hydroxychloroquine (105), or ciclosporin (106) are indirect inhibitors of NLRP3. Conversely, glucocorticoids induce NLRP3 overexpression (107), which suggests that NLRP3 inhibitors may act synergistically and could, potentially, solve the problem of glucocorticoid resistance in inflammatory and haematologic diseases. Altogether, this highlights the potential

benefits to human health of fully understanding the mechanisms by which the
NLRP3 inflammasome is negatively regulated.

Acknowledgements

The authors (EC, JP and MMcD) are supported by the EU Horizon 2020 research
and innovation program (ImmunAID; grant agreement number 779295); FR is
supported the Foundation for Development of Internal Medicine in Europe (FDIME),
the European Federation of Internal Medicine (EFIM), and the French National
Society for Internal Medicine (SNFMI).

Immunome project consortium for Autoinflammatory Disorders (ImmunAID)

Emily A. Caseley¹, James A. Poulter¹ and Michael F. McDermott¹

¹ Leeds Institute of Rheumatic and Musculoskeletal Medicine, St James's University
Hospital, Leeds, UK

Conflict of interest

The authors declare that they have no conflict of interest.

References

1. Cassel SL, Sutterwala FS. Sterile inflammatory responses mediated by the
NLRP3 inflammasome. Eur J Immunol. 2010; 40(3): 607-11.

527 2. Bauernfeind F, Hornung V. Of inflammasomes and pathogens—sensing of
528 microbes by the inflammasome. *EMBO Mol Med.* 2013; 5(6): 814-26.

529 3. Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and
530 signalling. *Nat Rev Immunol.* 2016; 16(7): 407.

531 4. Krainer J, Siebenhandl S, Weinhäusel A. Systemic autoinflammatory diseases. *J*
532 *Autoimmun.* 2020: 102421.

533 5. Scambler T, Jarosz-Griffiths HH, Lara-Reyna S, Pathak S, Wong C, Holbrook J, et
534 al. ENaC-mediated sodium influx exacerbates NLRP3-dependent inflammation in
535 cystic fibrosis. *eLife.* 2019; 8.

536 6. Savic S, Caseley EA, McDermott MF. Moving towards a systems-based
537 classification of innate immune-mediated diseases. *Nat Rev Rheumatol.* 2020: 1-16.

538 7. Moossavi M, Parsamanesh N, Bahrami A, Atkin SL, Sahebkar A. Role of the
539 NLRP3 inflammasome in cancer. *Mol Cancer.* 2018; 17(1): 158.

540 8. Harrison SR, McGonagle D, Nizam S, Jarrett S, Van der Hilst J, McDermott MF, et
541 al. Anakinra as a diagnostic challenge and treatment option for systemic
542 autoinflammatory disorders of undefined etiology. *JCI Insight.* 2016; 1(6).

543 9. Vande Walle L, Kanneganti T-D, Lamkanfi M. HMGB1 release by inflammasomes.
544 *Virulence.* 2011; 2(2): 162-5.

545 10. Zahid A, Li B, Kombe JK, Jin T, Tao J. Pharmacological Inhibitors of the NLRP3
546 Inflammasome. *Front Immunol.* 2019; 10: 2538.

547 11. Hoffman HM. Therapy of autoinflammatory syndromes. *J Allergy Clin Immunol.*
548 2009; 124(6): 1129-38.

549 12. Wekell P, Berg S, Karlsson A, Fasth A. Toward an inclusive, congruent, and
550 precise definition of autoinflammatory diseases. *Front Immunol.* 2017; 8: 497.

551 13. Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA.
552 Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease.
553 *Circ Res.* 2020; 126(9): 1260-80.

554 14. Romberg N, Vogel TP, Canna SW. NLRC4 inflammasomopathies. *Curr Opin*
555 *Allergy Clin Immunol.* 2017; 17(6): 398.

556 15. Coll RC, Robertson AA, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, et
557 al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of
558 inflammatory diseases. *Nat Med.* 2015; 21(3): 248.

559 16. He H, Jiang H, Chen Y, Ye J, Wang A, Wang C, et al. Oridonin is a covalent
560 NLRP3 inhibitor with strong anti-inflammasome activity. *Nat Commun.* 2018; 9(1): 1-
561 12.

562 17. Jiang H, He H, Chen Y, Huang W, Cheng J, Ye J, et al. Identification of a
563 selective and direct NLRP3 inhibitor to treat inflammatory disorders. *J Exp Med.*
564 2017; 214(11): 3219-38.

565 18. Sarrauste de Menthère C, Terriere S, Pugnere D, Ruiz M, Demaille J, Touitou I.
566 INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations.
567 *Nucleic Acids Res.* 2003; 31(1): 282-5.

568 19. Walle LV, Stowe IB, Šácha P, Lee BL, Demon D, Fossoul A, et al.
569 MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not
570 disease-associated mutants for inflammasome inhibition. *PLoS Biol.* 2019; 17(9):
571 e3000354.

572 20. Nakanishi H, Prakash P, Ito T, Kim HJ, Brewer CC, Harrow D, et al. Genetic
573 hearing loss associated with autoinflammation. *Front Neurol.* 2020; 11.

574 21. de Jesus AA, Hou Y, Brooks S, Malle L, Biancotto A, Huang Y, et al. Distinct
575 interferon signatures and cytokine patterns define additional systemic
576 autoinflammatory diseases. *J Clinical Invest.* 2020; 130(4).

577 22. Poulter JA, McDermott MA. Faculty Opinions Recommendation of [de Jesus AA
578 et al., *J Clin Invest* 2020]. *Faculty Opinions.* 2020.

579 23. Gram H. The long and winding road in pharmaceutical development of
580 canakinumab from rare genetic autoinflammatory syndromes to myocardial infarction
581 and cancer. *Pharmacol Res.* 2019: 104139.

582 24. Cavalli G, Dinarello CA. Anakinra therapy for non-cancer inflammatory diseases.
583 *Front Pharmacol.* 2018; 9: 1157.

584 25. Coburn LA, Horst SN, Chaturvedi R, Brown CT, Allaman MM, Scull BP, et al.
585 High-throughput multi-analyte Luminex profiling implicates eotaxin-1 in ulcerative
586 colitis. *PloS One.* 2013; 8(12).

587 26. Monastero RN, Pentyla S. Cytokines as biomarkers and their respective clinical
588 cutoff levels. *Int J Inflamm.* 2017; 2017.

589 27. Bauernfeind F, Rieger A, Schildberg FA, Knolle PA, Schmid-Burgk JL, Hornung
590 V. NLRP3 inflammasome activity is negatively controlled by miR-223. *J Immunol.*
591 2012; 189(8): 4175-81.

592 28. Misawa T, Takahama M, Kozaki T, Lee H, Zou J, Saitoh T, et al. Microtubule-
593 driven spatial arrangement of mitochondria promotes activation of the NLRP3
594 inflammasome. *Nat Immunol.* 2013; 14(5): 454.

595 29. Mortimer L, Moreau F, MacDonald JA, Chadee K. NLRP3 inflammasome
596 inhibition is disrupted in a group of auto-inflammatory disease CAPS mutations. *Nat*
597 *Immunol.* 2016; 17(10): 1176.

598 30. Indramohan M, Stehlik C, Dorfleutner A. COPs and POPs patrol inflammasome
599 activation. *J Mol Biol.* 2018; 430(2): 153-73.

600 31. Kahlenberg JM, Dubyak GR. Mechanisms of caspase-1 activation by P2X7
601 receptor-mediated K⁺ release. *Am J Physiol Cell Physiol.* 2004; 286(5): C1100-C8.

602 32. Hu Y, Mao K, Zeng Y, Chen S, Tao Z, Yang C, et al. Tripartite-motif protein 30
603 negatively regulates NLRP3 inflammasome activation by modulating reactive oxygen
604 species production. *J Immunol.* 2010; 185(12): 7699-705.

605 33. Jin J, Yu Q, Han C, Hu X, Xu S, Wang Q, et al. LRRFIP2 negatively regulates
606 NLRP3 inflammasome activation in macrophages by promoting Flightless-I-mediated
607 caspase-1 inhibition. *Nat Commun.* 2013; 4(1): 1-8.

608 34. Carpentier SJ, Ni M, Duggan JM, James RG, Cookson BT, Hamerman JA. The
609 signaling adaptor BCAP inhibits NLRP3 and NLRC4 inflammasome activation in
610 macrophages through interactions with Flightless-1. *Sci Signal.* 2019; 12(581):
611 eaau0615.

612 35. Kubota T, Koike R. Cryopyrin-associated periodic syndromes: background and
613 therapeutics. *Mod Rheumatol.* 2010; 20(3): 213-21.

614 36. Shim D-W, Lee K-H. Posttranslational regulation of the NLR family pyrin domain-
615 containing 3 inflammasome. *Front Immunol.* 2018; 9: 1054.

616 37. Swanson KV, Deng M, Ting JP-Y. The NLRP3 inflammasome: molecular
617 activation and regulation to therapeutics. *Nat Rev Immunol.* 2019; 19(8): 477-89.

618 38. Yang Y, Wang H, Kouadir M, Song H, Shi F. Recent advances in the
619 mechanisms of NLRP3 inflammasome activation and its inhibitors. *Cell Death Dis.*
620 2019; 10(2): 1-11.

621 39. Song N, Li T. Regulation of NLRP3 inflammasome by phosphorylation. *Front*
622 *Immunol.* 2018; 9:2305.

623 40. Sokolowska M, Chen L-Y, Liu Y, Martinez-Anton A, Qi H-Y, Logun C, et al.
624 Prostaglandin E2 inhibits NLRP3 inflammasome activation through EP4 receptor and
625 intracellular cyclic AMP in human macrophages. *J Immunol.* 2015; 194(11): 5472-87.

626 41. Zhang Z, Meszaros G, He W-t, Xu Y, de Fatima Magliarelli H, Mailly L, et al.
627 Protein kinase D at the Golgi controls NLRP3 inflammasome activation. *J Exp Med.*
628 2017; 214(9): 2671-93.

629 42. Liu X, Pichulik T, Wolz O-O, Dang T-M, Stutz A, Dillen C, et al. Human NACHT,
630 LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is
631 regulated by and potentially targetable through Bruton tyrosine kinase. *J Allergy Clin*
632 *Immunol.* 2017; 140(4): 1054-67. e10.

633 43. Mao L, Kitani A, Hiejima E, Montgomery-Recht K, Zhou W, Fuss I, et al. Bruton
634 tyrosine kinase deficiency augments NLRP3 inflammasome activation and causes
635 IL-1 β -mediated colitis. *J Clin Invest.* 2020; 130(4): 1793-1807.

636 44. Bittner ZA, Liu X, Dickhoefer S, Kalbacher H, Bosch K, Andreeva L, et al. BTK
637 operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity.
638 *bioRxiv.* 2019: 864702.

639 45. Sharif H, Wang L, Wang WL, Magupalli VG, Andreeva L, Qiao Q, et al. Structural
640 mechanism for NEK7-licensed activation of NLRP3 inflammasome. *Nature*. 2019;
641 570(7761): 338-43.

642 46. Han S, Lear TB, Jerome JA, Rajbhandari S, Snaveley CA, Gulick DL, et al.
643 Lipopolysaccharide primes the NALP3 inflammasome by inhibiting its ubiquitination
644 and degradation mediated by the SCFFBXL2 E3 ligase. *J Biol Chem*. 2015; 290(29):
645 18124-33.

646 47. Barry R, John SW, Liccardi G, Tenev T, Jaco I, Chen C-H, et al. SUMO-
647 mediated regulation of NLRP3 modulates inflammasome activity. *Nat Commun*.
648 2018; 9(1): 1-14.

649 48. Paramel G, Sirsjö A, Fransén K. Role of genetic alterations in the NLRP3 and
650 CARD8 genes in health and disease. *Mediat Inflamm*. 2015; 2015: 846782.

651 49. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3
652 forms an IL-1 β -processing inflammasome with increased activity in Muckle-Wells
653 autoinflammatory disorder. *Immunity*. 2004; 20(3): 319-25.

654 50. Ito S, Hara Y, Kubota T. CARD8 is a negative regulator for NLRP3
655 inflammasome, but mutant NLRP3 in cryopyrin-associated periodic syndromes
656 escapes the restriction. *Arthritis Res Ther*. 2014; 16(1): R52.

657 51. Cheung MS, Theodoropoulou K, Lugin J, Martinon F, Busso N, Hofer M.
658 Periodic fever with aphthous stomatitis, pharyngitis, and cervical adenitis syndrome
659 is associated with a CARD8 variant unable to bind the NLRP3 inflammasome. *J*
660 *Immunol*. 2017; 198(5): 2063-9.

661 52. Mao L, Kitani A, Similuk M, Oler AJ, Albenberg L, Kelsen J, et al. Loss-of-
662 function CARD8 mutation causes NLRP3 inflammasome activation and Crohn's
663 disease. *J Clin Invest.* 2018; 128(5): 1793-806.

664 53. Haq T, Richards MW, Burgess SG, Gallego P, Yeoh S, O'Regan L, et al.
665 Mechanistic basis of Nek7 activation through Nek9 binding and induced dimerization.
666 *Nat Commun.* 2015; 6(1): 1-12.

667 54. He Y, Zeng MY, Yang D, Motro B, Núñez G. NEK7 is an essential mediator of
668 NLRP3 activation downstream of potassium efflux. *Nature.* 2016; 530(7590): 354-7.

669 55. Shi H, Wang Y, Li X, Zhan X, Tang M, Fina M, et al. NLRP3 activation and
670 mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome
671 component. *Nat Immunol.* 2015; 17(3): 250–8.

672 56. Chen X, Liu G, Yuan Y, Wu G, Wang S, Yuan L. NEK7 interacts with NLRP3 to
673 modulate the pyroptosis in inflammatory bowel disease via NF- κ B signaling. *Cell*
674 *Death Dis.* 2019; 10(12): 1-12.

675 57. Matsubayashi T, Sugiura H, Arai T, Oh-Ishi T, Inamo Y. Anakinra therapy for
676 CINCA syndrome with a novel mutation in exon 4 of the CIAS1 gene. *Acta Paediatr.*
677 2006; 95(2): 246-9.

678 58. Jesus AA, Silva CA, Segundo GR, Aksentijevich I, Fujihira E, Watanabe M, et al.
679 Phenotype–genotype analysis of cryopyrin-associated periodic syndromes (CAPS):
680 description of a rare non-exon 3 and a novel CIAS1 missense mutation. *J Clin*
681 *Immunol.* 2008; 28(2): 134.

682 59. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the
683 molecular pathophysiology of autoinflammatory disease. *Annu Rev Immunol.* 2009;
684 27: 621-68.

685 60. Walker JE, Saraste M, Runswick MJ, Gay NJ. Distantly related sequences in the
686 alpha-and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring
687 enzymes and a common nucleotide binding fold. *EMBO J.* 1982; 1(8): 945-51.

688 61. Duncan JA, Bergstralh DT, Wang Y, Willingham SB, Ye Z, Zimmermann AG, et
689 al. Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to
690 mediate inflammatory signaling. *PNAS.* 2007; 104(19): 8041-6.

691 62. Coll RC, Hill JR, Day CJ, Zamoshnikova A, Boucher D, Massey NL, et al.
692 MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome
693 inhibition. *Nat Chem Biol.* 2019; 15(6): 556-9.

694 63. Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, et al.
695 De novo CIAS1 mutations, cytokine activation, and evidence for genetic
696 heterogeneity in patients with neonatal-onset multisystem inflammatory disease
697 (NOMID): a new member of the expanding family of pyrin-associated
698 autoinflammatory diseases. *Arthritis Rheum.* 2002; 46(12): 3340-8.

699 64. Caroli F, Pontillo A, D'Ossualdo A, Travan L, Ceccherini I, Crovella S, et al.
700 Clinical and genetic characterization of Italian patients affected by CINCA syndrome.
701 *Rheumatology.* 2007; 46(3): 473-8.

702 65. Zhang L, Chen S, Ruan J, Wu J, Tong AB, Yin Q, et al. Cryo-EM structure of the
703 activated NAIP2-NLRC4 inflammasome reveals nucleated polymerization. *Science.*
704 2015; 350(6259): 404-9.

705 66. Hu Z, Yan C, Liu P, Huang Z, Ma R, Zhang C, et al. Crystal structure of NLRC4
706 reveals its autoinhibition mechanism. *Science*. 2013; 341(6142): 172-5.

707 67. Matyszewski M, Zheng W, Lueck J, Antiochos B, Egelman EH, Sohn J. Cryo-EM
708 structure of the NLRC4CARD filament provides insights into how symmetric and
709 asymmetric supramolecular structures drive inflammasome assembly. *J Biol Chem*.
710 2018; 293(52): 20240-8.

711 68. Oroz J, Barrera-Vilarmau S, Alfonso C, Rivas G, de Alba E. ASC pyrin domain
712 self-associates and binds NLRP3 protein using equivalent binding interfaces. *J Biol*
713 *Chem*. 2016; 291(37): 19487-501.

714 69. Vajjhala PR, Mirams RE, Hill JM. Multiple binding sites on the pyrin domain of
715 ASC protein allow self-association and interaction with NLRP3 protein. *J Biol Chem*.
716 2012; 287(50): 41732-43.

717 70. Bae JY, Park HH. Crystal structure of NALP3 protein pyrin domain (PYD) and its
718 implications in inflammasome assembly. *J Biol Chem*. 2011; 286(45): 39528-36.

719 71. Abais JM, Xia M, Zhang Y, Boini KM, Li P-L. Redox regulation of NLRP3
720 inflammasomes: ROS as trigger or effector? *Antioxid Redox Sign*. 2015; 22(13):
721 1111-29.

722 72. Hoffman HM, Scott P, Mueller JL, Misaghi A, Stevens S, Yancopoulos GD, et al.
723 Role of the leucine-rich repeat domain of cryopyrin/NALP3 in monosodium urate
724 crystal-induced inflammation in mice. *Arthritis Rheum*. 2010; 62(7): 2170-9.

725 73. Latz E. The inflammasomes: mechanisms of activation and function. *Curr Opin*
726 *Immunol*. 2010; 22(1): 28-33.

727 74. Py BF, Kim M-S, Vakifahmetoglu-Norberg H, Yuan J. Deubiquitination of NLRP3
728 by BRCC3 critically regulates inflammasome activity. *Mol Cell*. 2013; 49(2): 331-8.

729 75. Hoss F, Mueller JL, Ringeling FR, Rodriguez-Alcazar JF, Brinkschulte R, Seifert
730 G, et al. Alternative splicing regulates stochastic NLRP3 activity. *Nat Commun*. 2019;
731 10(1): 1-13.

732 76. Dowds TA, Masumoto J, Zhu L, Inohara N, Núñez G. Cryopyrin-induced
733 Interleukin 1 β Secretion in Monocytic Cells Enhanced Activity Of Disease-Associated
734 Mutants and Requirement for ASC. *J Biol Chem*. 2004; 279(21): 21924-8.

735 77. Martinon F, Agostini L, Meylan E, Tschopp J. Identification of bacterial muramyl
736 dipeptide as activator of the NALP3/cryopyrin inflammasome. *Curr Biol*. 2004;
737 14(21): 1929-34.

738 78. Hafner-Bratkovič I, Sušjan P, Lainšček D, Tapia-Abellán A, Cerović K, Kadunc L,
739 et al. NLRP3 lacking the leucine-rich repeat domain can be fully activated via the
740 canonical inflammasome pathway. *Nat Commun*. 2018; 9(1): 1-18.

741 79. Koda A, Nagai H, Watanabe S, Yanagihara Y, Sakamoto K. Inhibition of
742 hypersensitivity reactions by a new drug, N (3', 4'-dimethoxycinnamoyl) anthranilic
743 acid (N-5'). *J Allergy Clin Immunol*. 1976; 57(5): 396-407.

744 80. Huang Y, Jiang H, Chen Y, Wang X, Yang Y, Tao J, et al. Tranilast directly
745 targets NLRP3 to treat inflammasome-driven diseases. *EMBO Mol Med*. 2018; 10(4).

746 81. He Y, Varadarajan S, Muñoz-Planillo R, Burberry A, Nakamura Y, Núñez G. 3, 4-
747 methylenedioxy- β -nitrostyrene inhibits NLRP3 inflammasome activation by blocking
748 assembly of the inflammasome. *J Biol Chem*. 2014; 289(2): 1142-50.

749 82. Juliana C, Fernandes-Alnemri T, Wu J, Datta P, Solorzano L, Yu J-W, et al. Anti-
750 inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the
751 inflammasome. *J Biol Chem*. 2010; 285(13): 9792-802.

752 83. Shim D-W, Shin W-Y, Yu S-H, Kim B-H, Ye S-K, Koppula S, et al. BOT-4-one
753 attenuates NLRP3 inflammasome activation: NLRP3 alkylation leading to the
754 regulation of its ATPase activity and ubiquitination. *Sci Rep*. 2017; 7(1): 1-12.

755 84. Perregaux DG, McNiff P, Laliberte R, Hawryluk N, Peurano H, Stam E, et al.
756 Identification and characterization of a novel class of interleukin-1 post-translational
757 processing inhibitors. *J Pharmacol Exp Ther*. 2001; 299(1): 187-97.

758 85. Tapia-Abellán A, Angosto-Bazarra D, Martínez-Banaclocha H, de Torre-Minguela
759 C, Cerón-Carrasco JP, Pérez-Sánchez H, et al. MCC950 closes the active
760 conformation of NLRP3 to an inactive state. *Nat Chem Biol*. 2019; 15(6): 560-4.

761 86. Śledź P, Caflisch A. Protein structure-based drug design: from docking to
762 molecular dynamics. *Curr Opin Struc Biol*. 2018; 48: 93-102.

763 87. Abdullaha M, Mohammed S, Ali M, Kumar A, Vishwakarma RA, Bharate SB.
764 Discovery of quinazolin-4 (3 H)-ones as NLRP3 inflammasome inhibitors:
765 computational design, metal-free synthesis, and in vitro biological evaluation. *J Org*
766 *Chem*. 2019; 84(9): 5129-40.

767 88. Lu A, Magupalli VG, Ruan J, Yin Q, Atianand MK, Vos MR, et al. Unified
768 polymerization mechanism for the assembly of ASC-dependent inflammasomes.
769 *Cell*. 2014; 156(6): 1193-206.

770 89. Pal A, Neo K, Rajamani L, Ferrer FJ, Lane DP, Verma CS, et al. Inhibition of
771 NLRP3 inflammasome activation by cell-permeable stapled peptides. *Sci Rep.* 2019;
772 9(1): 1-15.

773 90. Chang W-C, Chu M-T, Hsu C-Y, Wu Y-JJ, Lee J-Y, Chen T-J, et al. Rhein, an
774 Anthraquinone drug, suppresses the NLRP3 Inflammasome and macrophage
775 activation in urate crystal-induced gouty inflammation. *Am J Chinese Med.* 2019;
776 47(01): 135-51.

777 91. Wally V, Hovnanian A, Ly J, Buckova H, Brunner V, Lettner T, et al. Diacerein
778 orphan drug development for epidermolysis bullosa simplex: A phase 2/3
779 randomized, placebo-controlled, double-blind clinical trial. *J Am Acad Dermatol.*
780 2018; 78(5): 892-901. e7.

781 92. Marchetti C, Swartzwelter B, Gamboni F, Neff CP, Richter K, Azam T, et al.
782 OLT1177, a β -sulfonyl nitrile compound, safe in humans, inhibits the NLRP3
783 inflammasome and reverses the metabolic cost of inflammation. *PNAS.* 2018;
784 115(7): E1530-E9.

785 93. Jansen T, Klück V, Janssen M, Comarniceanu A, Efdé M, Scribner C, et al. P160
786 The first phase 2A proof-of-concept study of a selective NLRP3 inflammasome
787 inhibitor, dapansutrole™ (OLT1177™), in acute gout. *BMJ Publishing Group Ltd;*
788 2019.

789 94. Inzomelid completes Phase I studies and shows positive results in the treatment
790 of Cryopyrin-Associated Periodic Syndrome (CAPS). March 26, 2020.

791 95. Darakhshan S, Pour AB. Tranilast: a review of its therapeutic applications.
792 *Pharmacol Res.* 2015; 91: 15-28.

793 96. Mangan MS, Olhava EJ, Roush WR, Seidel HM, Glick GD, Latz E. Targeting the
794 NLRP3 inflammasome in inflammatory diseases. *Nat Rev Drug Discov.* 2018; 17(8):
795 588.

796 97. Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N, et al. Masitinib
797 (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. *PloS One.*
798 2009; 4(9).

799 98. Cikovic T. Effects of Small Molecules and Cytokine Signalling on NLRP3
800 Inflammasome Activation: Technische Universität München; 2019.

801 99. Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hernández M, et al. Masitinib
802 as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a
803 randomized clinical trial. *Amyotrophic Lateral Sclerosis and Frontotemporal*
804 *Degeneration.* 2020; 21(1-2): 5-14.

805 100. Science A. Masitinib significantly delays disability progression on EDSS in
806 patients with primary progressive (PPMS) and non-active secondary progressive
807 (nSPMS) multiple sclerosis. [https://ml-](https://ml-euglobenewswire.com/Resource/Download/d25365b6-ead0-41fe-8f52-7d0819226318)
808 [euglobenewswire.com/Resource/Download/d25365b6-ead0-41fe-8f52-](https://ml-euglobenewswire.com/Resource/Download/d25365b6-ead0-41fe-8f52-7d0819226318)
809 [7d0819226318.](https://ml-euglobenewswire.com/Resource/Download/d25365b6-ead0-41fe-8f52-7d0819226318) 2020.

810 101. Science A. Interim results of masitinib study in Alzheimer's disease: positive
811 trend of efficacy in one of the doses tested [http://wwwab-](http://www.ab-science.com/images/_pdf/CP_AD_Interim_VEng_VFpdf)
812 [science.com/images/_pdf/CP_AD_Interim_VEng_VFpdf.](http://www.ab-science.com/images/_pdf/CP_AD_Interim_VEng_VFpdf) 2019.

813 102. Maier NK, Crown D, Liu J, Leppla SH, Moayeri M. Arsenic trioxide and other
814 arsenical compounds inhibit the NLRP1, NLRP3, and NAIP5/NLRC4
815 inflammasomes. *J Immunol.* 2014; 192(2): 763-70.

816 103. The NLRP3-CASP1 Inflammasome Induces Glucocorticoid Resistance in ALL.
817 Cancer Discov. 2015; 5(7): 18.

818 104. Pang Z, Wang G, Ran N, Lin H, Wang Z, Guan X, et al. Inhibitory effect of
819 methotrexate on rheumatoid arthritis inflammation and comprehensive metabolomics
820 analysis using ultra-performance liquid chromatography-quadrupole time of flight-
821 mass spectrometry (UPLC-Q/TOF-MS). Int J Mol Sci. 2018; 19(10): 2894.

822 105. Tang T-T, Lv L-L, Pan M-M, Wen Y, Wang B, Li Z-L, et al. Hydroxychloroquine
823 attenuates renal ischemia/reperfusion injury by inhibiting cathepsin mediated NLRP3
824 inflammasome activation. Cell Death Dis. 2018; 9(3): 1-14.

825 106. Iyer SS, He Q, Janczy JR, Elliott EI, Zhong Z, Olivier AK, et al. Mitochondrial
826 cardiolipin is required for Nlrp3 inflammasome activation. Immunity. 2013; 39(2):
827 311-23.

828 107. Busillo JM, Azzam KM, Cidlowski JA. Glucocorticoids sensitize the innate
829 immune system through regulation of the NLRP3 inflammasome. J Biol Chem. 2011;
830 286(44): 38703-13.

831

832 **Figure legends**

833 **Figure 1: The NLRP3/NEK7 complex domains and related CAPS mutations**

834 A 3D cartoon representation of NLRP3 in complex with NEK7 is shown on the left,
835 with the pyrin domain omitted from NLRP3 and the N-lobe from NEK7. Domains are
836 colour-coded as outlined in the 2D depiction on the right, with domains not
837 represented show in grey. Validated disease-causing CAPS mutations are shown as
838 yellow sticks and are described in further detail in Supplementary Table 2.

839

840 **Figure 2: PKA-mediated NLRP3 inhibition pathway and the relevant CAPS** 841 **mutations**

842 The protein kinase A (PKA) signalling pathway is shown on the left. Activation of the
843 EP4 receptor by prostaglandin E2 (PGE2) binding causes the Gas subunit to
844 dissociate from the receptor. Gas, in turn, induces adenylate cyclase (AC) activity,
845 which mediates the synthesis of ATP into cyclic adenosine monophosphate (cAMP),
846 which subsequently activates protein kinase A (PKA), leading to the PKA-mediated
847 phosphorylation of Ser295. This phosphorylation is disrupted by the NLRP3
848 mutations shown in the white box. The location of CAPS-related amino acids is
849 shown on the right, in both the whole receptor (top) and a magnified view (bottom),
850 with yellow sticks representing mutated residues and blue sticks showing
851 phosphorylated residues.

852

853 **Figure 3: PKD-mediated NLRP3 activation pathway and the relevant CAPS** 854 **mutations**

The protein kinase D (PKD) signalling pathway is shown on the left. Mitochondria-associated endoplasmic reticulum membranes (MAMs) localise adjacent to Golgi membranes in response to inflammasome activators, which is related to enhanced diacylglycerol (DAG) production at the Golgi. DAG, in turn, binds to PKD, which phosphorylates NLRP3 proteins retained at MAMs adjacent to the Golgi at Ser295. This phosphorylation allows NLRP3 to dissociate from the MAMs and assemble into the active inflammasome. The location of CAPS-related amino acids is shown on the right, in both the whole receptor (top) and a magnified view (bottom), with yellow sticks representing mutated residues and blue sticks showing phosphorylated residues.

Figure 4: BTK-mediated NLRP3 modification pathway and the relevant CAPS mutations

The bruton tyrosine kinase (BTK) signalling pathway is shown on the left. BTK is rapidly activated by NLRP3 inflammasome activators, and modifies four tyrosines in NLRP3 (Y136, Y140, Y143 and Y168). This alteration weakens the interactions between NLRP3 and phosphatidylinositol-4-phosphate (PtdIns4P) at the Golgi membrane, leading to dispersion and subsequent oligomerisation of NLRP3. The location of CAPS-related amino acids is shown on the right, in both the whole receptor (top) and a magnified view (bottom), with yellow sticks representing mutated residues and blue sticks showing phosphorylated residues.

Figure 5: CAPS mutations affecting NLRP3 sumoylation

878 Residues implicated in CAPS disruption of NLRP3 sumoylation are shown in the
879 protein as a whole (top) and as a magnified view (bottom), with yellow sticks
880 representing mutated residues and blue sticks showing the sumoylated residue.

881

882 **Figure 6: CAPS mutations affecting NLRP3/NEK7 interactions**

883 Residues implicated in CAPS disruption of NLRP3/NEK7 interactions are shown in
884 the protein as a whole (top) and as a magnified view (bottom), with yellow sticks
885 representing mutated residues.

886

887 **Table 1: NLRP3 inflammasome inhibitors in clinical trials**